Macrophage-inducible C-type lectin activates B cells to promote T cell reconstitution in heart allograft recipients

Suheyla Hasgur | Yosuke Yamamoto | Ran Fan | Michael Nicosia | Victoria Gorbacheva | Daniel Zwick | Motoo Araki | Robert L. Fairchild | Anna Valujskikh

INTRODUCTION

Antibody-mediated lymphoablation is a commonly used therapy in solid organ and stem cell transplantation and autoimmunity.1 Its efficacy is determined by the balance between the removal of pathogenic lymphocytes and preserving the individual’s ability to respond to opportunistic infections. In transplant recipients, T cell reconstitution following lymphoablation is the sum of potentially detrimental homeostatic proliferation of depletion-resistant memory T cells and beneficial thymopoiesis that replenishes non-alloreactive
T cells necessary for host protection. Diminishing the extent of homeostatic T cell proliferation is, therefore, essential for improving the efficacy of clinical lymphoablation. Previously, several factors were implicated in driving T cell homeostatic expansion, including costimulatory signals, IL-7, and antigens from commensal microorganisms. However, these studies
typically used whole-body irradiation, antibody-mediated depletion, or adoptive T cell transfer into lymphopenic hosts in the absence of additional systemic inflammation induced by autoimmunity or transplantation. Our recent studies in mouse heart transplantation models using a murine analog of anti-thymocyte globulin (mATG) revealed distinct mechanisms underlying homeostatic T cell expansion in the recipients. We found that the rapid T cell reconstitution in transplant recipients does not depend on specificity for donor alloantigens suggesting an important role for posttransplant inflammation. Depletion-resistant memory CD4+ T cells provide helper signals essential for CD8+ T cell homeostatic reconstitution. Furthermore, B cells activated via CD40 signaling are central mediators of B cell reconstitution following mATG induction therapy. During the search of additional mediators of B cell activation in mATG-treated allograft recipients, we identified and validated the importance of the C-type lectin receptor Clec-4e (macrophage-inducible C-type lectin, or Mincle). In addition to being a sensor of microbial pathogen-associated molecular patterns (PAMPs), both human and mouse Mincle has been implicated in non-infectious inflammatory conditions including rheumatoid arthritis, multiple sclerosis, and post-ischemic inflammation. The goal of the current study was to identify mediators linking posttransplant inflammation with the activation of depletion-resistant B lymphocytes that ultimately drive T cell homeostatic proliferation following mATG induction therapy.

During the search of additional mediators of B cell activation in mATG-treated allograft recipients, we identified and validated the importance of the C-type lectin receptor Clec-4e (macrophage-inducible C-type lectin, or Mincle). In addition to being a sensor of microbial pathogen-associated molecular patterns (PAMPs), both human and mouse Mincle has been implicated in non-infectious inflammatory conditions including rheumatoid arthritis, multiple sclerosis, and post-ischemic inflammation. The goal of the current study was to identify mediators linking posttransplant inflammation with the activation of depletion-resistant B lymphocytes that ultimately drive T cell homeostatic proliferation following mATG induction therapy.
surgery or with 0.1 mg agonistic anti-CD40 mAb FGK4.5 on days 0 and 1 posttransplant (both from BioXCell). For the administration of synthetic Mincle agonist, non-transplanted B6 mice treated with 0.5 mg mATG on days 0 and 4 were additionally injected with trehalose-6,6-dibehenate (TDB, InvivoGen) at 4 mg/kg i.p. twice weekly for the experiment duration starting on day 2.
FIGURE 2 Mincle deficiency reduces B cells cytokine production in mATG treated heart allograft recipients. (A, B) B6.WT recipients of BALB/c heart allografts were treated with mATG. Spleen cells were analyzed for Mincle and IL-1β, IL-6, and TNFα expression at day 8 posttransplant. (A) Representative zebra plots after gating on B220+ cells. (B) Proportion of cytokine-producing B220+Mincle+ cells. Symbols represent individual recipients from one of two independent experiments. (C, D) B6.WT or B6.Mincle−/− mice were transplanted with BALB/c heart allografts and treated with mATG. The cytokine production by B cells was determined by intracellular flow cytometry on days 8 and 12 posttransplant. (C) Representative dot plots (day 12) after gating on B220+ cells. (D) Quantification of the flow cytometry analysis at indicated time points. n = 4 animals/group; error bars represent SD.

2.4 | Bone marrow chimeras

Bone marrow was isolated from femurs of wild type B6, B6.Mincle−/− and B6.μMT mice. Female B6.μMT mice were irradiated (1100 rads) and injected i.v. with bone marrow cells so that each recipient received 5 × 10^5 μMT−/− cells plus 5 × 10^5 either WT or Mincle−/− cells as we previously described.4 4–5 weeks later, the resulting chimeras were transplanted with BALB/c heart allografts and treated with mATG.

2.5 | In vitro B cell stimulation

B cells were isolated from naïve B6.WT, or B6.Mincle−/− mice by EasySep immunomagnetic kit and incubated for 20 h in RPMI 1640 supplemented with 10% FBS and 2mM L-glutamine with or without the addition of 1 μg/ml LPS (Lipopolysaccharide from Escherichia coli O55:B5) (MilliporeSigma) or agonistic anti-CD40 mAb (10 μg/ml, clone FGK4.5; BioXcell). For intracellular cytokine staining, after 16 h of incubation cells were treated PMA (10 ng/ml, MilliporeSigma) and ionomycin (1 μM, MilliporeSigma) for 4 h plus 2 μM monensin (Biolegend) during the last 2 h of culture to inhibit cytokine release from the Golgi/endoplasmic reticulum complex. After incubation, cells were analyzed by flow cytometry for the expression of Mincle, IL-1β, IL-6, and TNFα.

2.6 | NanoString gene expression analysis

Gene expression analysis was performed using NanoString Mouse Immunology Panel (561 genes) as previously published4 (Supplementary Methods).

2.7 | Real-time PCR

RNA was isolated from spleen B220+ cells and subjected to reverse transcription with the High-Capacity cDNA Reverse Transcription Kit. Real-time PCR was performed on a 7500 Fast Real-Time PCR System instrument with the following probes and primers: Clec4e (Mm01183703_m1) and Card9 (Mm01327594_m1). All reagents were obtained from Applied Biosystems. Data were normalized to Mrpl32 (Mm00777741-s4) RNA amplification and the expression of the target gene in naïve spleen B cells.

2.8 | Flow cytometry

Fluorochrome-conjugated antibodies used in this study are listed in Table S1. Single-cell suspensions were prepared from peripheral blood and spleen. Following red blood cell lysis, the cells were aliquoted at 1 × 10^6/sample and stained as previously described.3,24 Cell viability was determined by staining with either SytoxTM Orange Nucleic Acid Stain or LIVE/DEADTM Fixable Aqua Dead Cell Stain (Invitrogen) as described in Supplementary Methods. At least 50,000 live events per sample were collected on an LSR Fortessa X-20 (BD Bioscience). The data were analyzed with FlowJo 10.8.1 (Tree Star Inc.).

2.9 | Statistics

GraphPad Prism 9.1 was used for all statistical analyses, and the results are presented as the mean ± SD. The comparison between groups was performed by two-tailed Student’s t-test (two groups), one-way analysis of variance (ANOVA) (three or more groups), and multiple t-tests (kinetics experiments). The graft survival was analyzed using the log-rank Mantel-Cox test.

3 | RESULTS

3.1 | Mincle expression is up-regulated in B cells following heart allograft transplantation and lymphoablation

We recently reported that IL-1β and IL-6 are produced by activated B cells and are critical for rapid homeostatic T cell reconstitution in allograft recipients treated with anti-mouse thymocyte globulin (mATG).5 To identify potential mediators of B cell activation and proinflammatory functions following lymphoablation, we purified B cells from the spleens of mATG treated B6 recipients of BALB/c heart allografts on day 12 posttransplant, isolated mRNA, and performed NanoString Gene Expression analysis (Mouse Immunology Panel, 561 genes). The control samples included B cells from untreated B6 recipients of BALB/c heart allografts and from allograft recipients treated with a combination of mATG and anti-CD4 depleting mAbs to eliminate helper signals to B cells. mATG lymphoablation upregulated B cell expression of over 30 genes >10-fold.4 In addition to proinflammatory cytokines, C-type lectin receptor Mincle and its signaling mediator CARD9 were among the top gene
FIGURE 3  B cell Mincle deficiency impairs T cell reconstitution after mATG lymphoablation in heart allograft recipients. (A–C) B6.WT or B6.Mincle−/− mice were transplanted with BALB/c heart allografts and treated with mATG (day 0 and 4). (A) Numbers of CD4+ and CD8+ T cells per 100 μl of peripheral blood. (B) Numbers of CD4+ and CD8+ T cells per recipient’s spleen at day 28 after transplantation. Symbols represent individual recipients. (C) Heart allograft survival. n = 7–11 animals/group. (D–E) Lethally irradiated B6.μMT mice were co-injected with bone marrow cells from either B6.μMT and B6.WT (BWT chimeras) or B6.μMT and B6.Mincle−/− mice (BΔMincle chimeras), followed by BALB/c heart transplantation and mATG treatment 4–5 weeks later. (D) Experimental design. (E) Numbers of CD4+ and CD8+ T cells per 100 μl of peripheral blood. The results of the representative experiment with n = 3–4 animals/group are shown. The experiment was performed one more time with similar results. (F, G) Non-transplanted B6.WT or B6.Mincle−/− mice were treated with mATG on days 0 and 4. The numbers of CD4+ and CD8+ T cells in peripheral blood (F) and spleen (G, day 28). n = 6–7 animals/group; error bars represent SD.
HASGUR ET AL.

The increases in the Mincle gene and protein expression in B cells were further confirmed by qRT-PCR and by flow cytometry (Figure 1B,C; Figure S1B). It is worth noting that the numbers of spleen B cells are only transiently reduced by mATG treatment and are restored to pre-depletion levels by day 8 after transplantation (not shown). By day 8 posttransplant, mATG treatment increased the proportion of spleen B220+Mincle+ cells in allograft recipients compared to heart allograft transplantation alone (Figure 1D). Thus, the total numbers of B220+Mincle+ cells were also increased in mATG-treated vs untreated heart allograft recipients (Figure 1E). A similar increase in B220+Mincle+ cells was observed after mATG treatment of heart isograft recipients (Figure 1E), with <1.5 × 10^6 per spleen B220+Mincle+ cells detected in untreated heart isograft recipients (not shown).

The analysis of CD11c+CD11c−, CD11b+CD11c+, and CD11b+CD11c+ myeloid cells revealed that Mincle expression in all these subsets is markedly up-regulated after heart allotransplantation alone and is further enhanced by concurrent mATG treatment (Figure S2). However, as mATG treatment significantly reduced the numbers of myeloid cells (not shown), more than half of Mincle+ cells in the spleen were B220+ (Figure 1E; Figure S2B).

While Mincle was initially identified as a pattern recognition receptor induced in macrophages by inflammatory stimuli including LPS, TNFα, IL-6, and IFNγ, the pattern of Mincle expression in mouse B lymphocytes has not been previously reported. Analogous to resting macrophages, B cells isolated from spleens of naive non-transplanted mice do not express Mincle. However, Mincle expression on B lymphocytes is induced after 20 h in vitro culture even in the absence of stimulation. While additional TLR4 or CD40 stimulation did not increase the proportion of Mincle-expressing cells or the level of Mincle expression on individual cells (as evidenced by MFI), it significantly enhanced B cell viability resulting in higher numbers of Mincle+ B cells at the end of the culture (Figure 1F–G). Taken together, these results demonstrated the ability of murine B cells to express Mincle both in vitro and in vivo and suggested that the Mincle pathway may contribute to B cell activation in mATG treated transplant recipients.

3.2 | Mincle is required for B cell proinflammatory cytokine production and rapid T cell reconstitution following lymphoablation

Analysis of cytokine production at day 8 after heart allotransplantation in mATG treated mice revealed that a significant proportion of Mincle+ B cells expressed IL-1β and TNFα (with a minority of IL-6 producers), suggesting that these cells contribute to the proinflammatory environment following lymphoablation (Figure 2A,B). To test the functional relevance of Mincle during T cell reconstitution, B6.WT or B6.Mincle−/− mice were transplanted with BALB/c heart allografts and treated with mATG. Recipient Mincle deficiency significantly decreased frequencies of B cells producing IL-1β, IL-6, and TNFα on days 8 and 12 posttransplant (Figure 2C,D). The reduced B cell activation in B6.Mincle−/− recipients was associated with delayed CD4+ and CD8+ T cell reconstitution in peripheral blood and spleen (Figure 3A,B). Consistent with slower T cell recovery, the heart allograft survival

![Figure 4: Treatment with Mincle agonist accelerates T cell reconstitution in the absence of heart transplantation. Non-transplanted B6.WT was injected with mATG on day 0 and 4 with or without treatment with synthetic Mincle agonist trehalose-6,6-dibehenate (TDB, twice weekly for 4 weeks). B6 recipients of BALB/c heart allografts treated with mATG are shown for comparison. The numbers of CD4+ and CD8+ T cells in peripheral blood (A) and spleen (B, day 28). The symbols represent individual animals; error bars represent SD.](image-url)
following mATG treatment was significantly prolonged in B6.Mincle−/− compared to B6.WT recipients (MST of 25 vs. 11 days, respectively, Figure 3C). To specifically test the role of Mincle in B cells, we generated two types of mixed bone marrow chimeras: WT + μMT BM → μMT (BWT, B cells express Mincle) and Mincle−/− + μMT BM → μMT (BΔMincle, Mincle is absent only in B cells) as we previously published.4 B cell-specific Mincle deletion resulted in significantly delayed T cell recovery after BALB/c heart transplantation and mATG treatment compared to control BWT chimeras (Figure 3D,E).

In contrast to the heart allograft model, recipient Mincle deficiency had a less prominent effect on the tempo of T cell reconstitution after transplantation of allogeneic skin grafts. B6.Mincle−/− recipients had lower spleen CD4+ T cell numbers after skin transplantation, while the numbers of CD8+ T cells were similar in both groups throughout the experiment (Figure S3). While skin graft tissue is mostly eliminated upon rejection, transplanted heart allografts remain in the recipient for the duration of the experiment. The observed differences in Mincle requirement between vascularized heart and non-vascularized skin allograft recipients suggest that Mincle signaling is activated via continuous release of DAMPs from the allograft into the recipient circulation. In line with this scenario, non-transplanted B6.WT and B6.Mincle−/− mice treated with mATG had similar kinetics of T cell reconstitution (Figure 3F,G). Taken together, these data indicate that Mincle serves as a sensor of persistent allograft-induced inflammation.

We next tested whether the delivery of exogenous Mincle ligand at the time of lymphoablation can substitute for heart allotransplantation in accelerating T cell reconstitution. Non-transplanted B6.WT mice were treated with two doses of mATG and additionally injected twice weekly with a synthetic Mincle agonist trehalose-6,6-dibehenate (TDB). While TDB treatment did not alter the efficacy of T cell depletion by mATG, it significantly increased CD4+ and CD8+ T cell recovery in the peripheral blood and spleen (Figure 4). These results indicate that Mincle-induced proinflammatory signaling is sufficient to drive T cell reconstitution even in the absence of ongoing alloresponse.

### 3.3 CD40 signaling facilitates T cell recovery via a Mincle-dependent pathway

We have previously reported that homeostatic reconstitution of recipient T cell repertoire following mATG lymphoablation is critically dependent on interactions between CD154 expressed by residual memory helper T cells and CD40 on B cells.2 The initial gene expression analysis showed that CD4 T cell help was required for Mincle up-regulation in B cells (Figure 1A). We further tested the relationship between CD40 and Mincle signaling pathways following lymphoablation. Administration of blocking anti-CD154 mAb at the time of mATG treatment and heart transplantation significantly reduced the proportion of Mincle+ B cells and B cells producing proinflammatory cytokines to the levels observed in recipients in the absence of lymphoablation (Figure 5A,B).

To test whether the critical role of CD40 signaling after lymphoablation is dependent on Mincle and proinflammatory cytokines, we treated heart allograft recipients with agonistic anti-CD40 mAb at the time of lymphoablation. As we previously reported,2 recipient CD4+ T cell depletion markedly diminished CD8 T cell homeostatic expansion, but anti-CD40 mAb FGK4.5 injection compensated for the lack of help in CD4-depleted recipients and partially restored CD8 T cell recovery (Figure 5C). In contrast, administration of agonistic anti-CD40 mAb had no effect on T cell reconstitution in Mincle−/− recipients (Figure 5D). Furthermore, anti-CD40 mAb treatment failed to promote T cell recovery in Casp-1−/− recipients unable to produce mature IL-1β (Figure 5E). In conjunction with our previous findings, these results suggest that CD40/CD154 pathway in this model acts primarily via enhancing Mincle signaling and proinflammatory cytokine production by B cells.

### 4 DISCUSSION

Despite the well-documented benefits of peritransplant lymphoablation for early graft function and prevention of acute rejection, the impact on long-term outcomes remains controversial.24–30 Our previous work established inflammation induced by transplant surgery and recipient B cells producing proinflammatory cytokines as important drivers of T cell reconstitution contributing to allograft rejection. In the current study, we identify C-type lectin Mincle as a receptor linking posttransplant inflammation and B cell activation in mATG treated allograft recipients.

Since the cloning of the Mincle gene in 1999, its expression, signaling, and functions in myeloid cells have been extensively characterized. To date, a single study demonstrated Mincle up-regulation...
in human B cells treated with a TLR9 ligand.\textsuperscript{22} Kawata et al. reported that the addition of a synthetic Mincle ligand trehalose-6,6'-dibehenate (TDB) decreased in vitro IgA and IgG release induced by TLR9 activation.\textsuperscript{22} Analogous to previous findings in myeloid cells and human B cells, we found that mouse B lymphocytes up-regulate Mincle expression after 20 h of in vitro culture even in the absence of stimulation (presumably via sensing DAMPs released by dying cells) and that the numbers of Mincle-expressing B cells are further increased by TLR4 or CD40 ligation. Importantly, our study is the first to detect up-regulation of Mincle on B lymphocytes in vivo and to show its functional relevance during an immune response. The studies are currently ongoing in the laboratory to address the functions of Mincle\textsuperscript{+} vs Mincle\textsuperscript{−} B cells in lymphopenic recipients with high resolution.

The current study is the first to investigate Mincle expression and contribution during the alloimmune response to transplanted organs. Presumably, the impact of Mincle and other pattern recognition receptors (PRRs) is more prominent in the settings of increased inflammation such as ischemia/reperfusion injury or massive cell death due to lymphophagocytosis. Following mATG treatment, recipient Mincle deficiency results in decreased B cytokine production and delayed T cell reconstitution ultimately leading to prolonged heart allograft survival (Figures 2 and 3). Conversely, providing exogenous Mincle ligand to mATG treated, non-transplanted mice enhanced T cell reconstitution indicating that Mincle ligation is both necessary and sufficient for this process (Figure 4).

While measuring T cell reconstitution in lymphopenic heart allograft recipients, it is important to consider the contribution of ongoing alloresponse as well as posttransplant inflammation. We have previously established that the rate of T cell expansion in heart allograft recipients treated with mATG does not depend on reactivity to donor alloantigens.\textsuperscript{23} In the current study, Mincle expression is equally upregulated in B cells from either allo-or isograft recipients (Figure 1E). This was unexpected given that the T cell reconstitution in heart isograft recipients treated with mATG is delayed compared to that in allograft recipients.\textsuperscript{5} One explanation for such results is that the early posttransplant injury and DAMPs release (including Mincle ligands) by an allograft exceeds that of an isograft and can thus have a stronger influence on T cell proliferation. This possibility is consistent with the similar T cell recovery in WT and Mincle\textsuperscript{−−} recipients of skin allografts that have a limited time of DAMPs release compared to heart transplants.

Our findings raise several questions including the precise mechanisms leading to Mincle up-regulation in B lymphocytes after transplantation with or without lymphophagocytosis, the identity of Mincle ligand(s) in heart allograft recipients, and the potential contribution of other Mincle-expressing cells besides B lymphocytes. Our data rule out the role of BCR signaling in Mincle up-regulation. Spleen B cells from isograft recipients increase Mincle expression after mATG treatment (Figure 1E), whereas B cells up-regulate Mincle expression in culture in the absence of BCR ligation (Figure 1G). Mincle expression in myeloid cells can be induced by a variety of factors, including TLR ligands, IL-6, TNFα, and IFNγ (reviewed in Refs. 7–10), of all of which are generated after allotransplantation. In addition, our data indicate that the B cell Mincle expression and cytokine production is critically dependent on CD40 signaling (Figure 5). Notably, heart transplantation without lymphophagocytosis is not sufficient to significantly up-regulate Mincle expression (Figure 1) most likely because CD40 signaling in lymphoreplete animals is limited to rare antigen-specific B cells. Mincle is one of the targets of the C/EBPβ transcription factor that can be activated by CD40 signaling in B cells.\textsuperscript{9,25,31} It remains to be determined whether CD40 signals in our model induce B cell Mincle expression directly or indirectly, for example via enhancing TLR signaling. Regardless of the exact mechanism, the ability of CD40 signaling to facilitate T cell reconstitution is critically dependent on the presence of Mincle (Figure 5).

While Mincle was originally described as a sensor of glycolipids from microbial pathogens, several ligands released by dying mammal cells have been eventually identified. To date, the established endogenous ligands include SAP-130,\textsuperscript{20} β-GlcCer,\textsuperscript{21} and cholesterol crystals,\textsuperscript{32} and it is likely that more Mincle ligands will be described in the future. Transplantation surgery, early alloresponses, and lymphophagocytosis-induced cell death all result in the release of various DAMPs.\textsuperscript{33–36} Based on our previously published findings and the data presented in this manuscript, we propose that after lymphophagocytosis, B cells receive CD40 signals from residual helper T cells leading to Mincle up-regulation and sensing of graft-derived circulating DAMPs through TLRs and Mincle. This results in the secretion of proinflammatory cytokines that either directly enhance T cell proliferation or amplify inflammation by further enhancing B cell cytokine production (Figure 6). Consistent with this model, T cell reconstitution is markedly accelerated in heart allograft recipients compared to non-transplanted mice implicating the graft as a major source of DAMPs.\textsuperscript{23} It is, therefore, not surprising that Mincle facilitates T cell recovery after heart allotransplantation, but not in non-transplanted mice or recipients of non-vascularized skin allografts (Figure 3).
Ongoing studies in the lab are investigating the biochemical nature of potential Mincle ligand(s) released by heart allografts with the ultimate goal of targeting these mediators to diminish posttransplant inflammation. As Mincle was shown to regulate antigen-presenting functions of myeloid cells, limiting this signaling pathway may lead to an additional benefit of decreased alloreactive T cell priming further promoting allograft survival.

We have previously established the central role of B lymphocytes following mATG lymphoablation, as B cell depletion or genetic deficiency significantly impairs T cell reconstitution. The absence of Mincle only in recipient B cells led to markedly delayed T cell recovery indicating the importance of this PRR in B lymphocyte activation following lymphoablation (Figure 3). Nevertheless, these data do not rule out the potential contribution of Mincle signaling in myeloid cells. In our previous studies, the depletion of CD11c+ cells using CD11c-DTR mice treated with diphtheria toxin (DT) did not influence T cell reconstitution (not shown). It is, therefore, suggestive, that the numbers of Mincle-expressing CD11b+CD11c+ but not CD11b−CD11c+ or CD11b+CD11c− cells are increased in mATG-treated heart allograft recipients compared to heart transplantation alone (Figure S2). The role of Mincle-expressing CD11b+ cells in the process of T cell recovery will be addressed in our future studies. It should be noted that the levels of Mincle expression in T lymphocytes were minimal after heart allotransplantation, and not affected by mATG treatment (not shown) making unlikely the direct influence of Mincle ligands on T lymphocytes.

In summary, our data indicate that following lymphoablation in the settings of transplantation, Mincle is required for recipient B cells to initiate production of proinflammatory cytokines and thus facilitate homeostatic T cell reconstitution. To our knowledge, this is the first report of the role of Mincle function in B lymphocytes in vivo. These findings identify Mincle and its endogenous ligands as potential therapeutic targets for minimizing the effects of posttransplant inflammation and improving the efficacy of lymphoablation in transplant recipients.

ACKNOWLEDGMENTS
The authors would like to thank Ms. Ashley Beavers for managing mouse colonies and generating animals for this study. The study was supported by NIAID R01 AI113142 (AV) and CTOT NanoString Core U01 AI063594 (RLF).

DISCLOSURE
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Robert L. Fairchild https://orcid.org/0000-0002-7107-5259
Anna Valujskikh https://orcid.org/0000-0003-3252-0636

REFERENCES
1. Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y. New directions for rabbit antithymocyte globulin (Thymoglobulin(R)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs. 2014;74(14):1605-1634.
2. Ayasoufi K, Fan R, Fairchild RL, Valujskikh A. CD4 T cell help via B cells is required for lymphopenia-induced CD8 T cell proliferation. J Immunol. 2016;196(7):3180-3190.
3. Ayasoufi K, Yu H, Fan R, Wang X, Williams J, Valujskikh A. Pretransplant antithymocyte globulin has increased efficacy in controlling donor-reactive memory T cells in mice. Am J Transplant. 2013;13(3):589-599.
4. Ayasoufi K, Zwick DB, Fan R, et al. Interleukin-27 promotes CD8+ T cell reconstitution following antibody-mediated lymphoablation. JCI Insight. 2019;4(7):e125489.
5. Hasgur S, Fan R, Zwick DB, Fairchild RL, Valujskikh A. B cell-derived IL-1beta and IL-6 drive T cell reconstitution following lymphoablation. Am J Transplant. 2020;20:2740-2754.
6. Del Fresno C, Iborra S, Szaj-Leaf P, Martinez-Lopez M, Sancho D. Flexible signaling of myeloid C-type lectin receptors in immunity and inflammation. Front Immunol. 2018;9:804.
7. Kingeter LM, Lin X. C-type lectin receptor-induced NF-kappaB activation in innate immune and inflammatory responses. Cell Mol Immunol. 2012;9(2):105-112.
8. Lu X, Nagata M, Yamasaki S. Mincle: 20 years of a versatile sensor. Cell Mol Immunol. 2014;11:285-328.
9. Ayasoufi K, Yu H, Fan R, Wang X, Williams J, Valujskikh A. Interleukin-27 promotes CD8+ T cell reconstitution following antibody-mediated lymphoablation. JCI Insight. 2019;4(7):e125489.
10. Richardson MB, Williams SJ. MCL and Mincle: C-type lectin receptor-mediated signaling of myeloid cells. Cell Mol Immunol. 2014;11:285-328.
11. Herczeg E, Lőrincz L, Varga K, et al. Mincle signaling promotes Con A hepatitis. JCI Insight. 2017;2(17):e92155.
12. Wu X, Guo JP, Yin FR, et al. Macrophage-inducible C-type lectin is associated with anti-cyclic citrullinated peptide antibodies-positive rheumatoid arthritis in men. Chin Med J (Engl). 2012;125(17):3115-3119.
13. Nakamura N, Shimaoka Y, Tougan T, et al. Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients. DNA Res. 2006;13(4):169-183.
14. N’diaye M, Brauner S, Slyzani S, et al. C-type lectin receptors Mcl and Mincle control development of multiple sclerosis-like neuroinflammation. J Clin Invest. 2020;130(2):838-852.
15. Arumugam TV, Manzanero S, Furtado M, et al. An atypical role for the myeloid receptor Mincle in central nervous system injury. J Cereb Blood Flow Metab. 2017;37(6):2098-2111.
16. Suzuki Y, Nakano Y, Mishiro K, et al. Involvement of Mincle and Syk in the myeloid receptor Mincle in central nervous system injury. J Cereb Blood Flow Metab. 2017;37(6):2098-2111.
17. Greco SH, Torres-Hernandez A, Kalabin A, et al. Mincle signaling promotes Con A hepatitis. J Immunol. 2016;197(7):2816-2827.
18. Te Velde AA. The C-type lectin Mincle: Clues for a role in Crohn’s disease adjuvant reaction. Front Immunol. 2017;8:1304.
19. Zhou H, Yu M, Zhao J, et al. IRAK-M-Mincle axis links cell death to inflammation: Pathophysiologic implications for chronic alcoholic liver disease. Hepatology. 2016;64(6):1798-1993.
20. Yamasaki S, Ishikawa E, Sakuma M, Hara H, Ogata K, Saito T. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol. 2008;9(10):1179-1188.
21. Nagata M, Izumi Y, Ishikawa E, et al. Intracellular metabolite beta-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity. Proc Natl Acad Sci USA 2017;114(16):E3285-E3294.
22. Kawata K, Illarionov P, Yang G-X, et al. Mincle and human B cell function. J Autoimmun. 2012;39(4):315-322.
23. Chen Y, Heeger PS, Valujskikh A. In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy. J Immunol. 2004;172(9):5456-5466.
24. Rabant M, Gorbachev V, Fan R, Yu H, Valujskikh A. CD40-independent help by memory CD4 T cells induces pathogenic alloantibody but does not lead to long-lasting humoral immunity. Am J Transplant. 2013;13(11):2831-2841.
25. Matsumoto M, Tanaka T, Kaisho T, et al. A novel LPS-inducible C-type lectin is a transcriptional target of NF-IL6 in macrophages. J Immunol. 1999;163(9):5039-5048.
26. Bunnapradist S, Takemoto SK. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant Proc. 2005;37(2):889-891.
27. Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation. 2006;81(9):1285-1289.
28. Libório AB, Mendoza TR, Esmeraldo RM, et al. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin. Int Immunopharmacol. 2011;11(11):1832-1836.
29. Martins L, Fonseca I, Almeida M, et al. Immunosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival. Transplant Proc. 2005;37(6):2755-2758.
30. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81(9):1227-1233.
31. Baccam M, Woo SY, Vinson C, Bishop GA. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP. J Immunol. 2003;170(6):3099-3108.
32. Kiyotake R, Oh-Hora M, Ishikawa E, Miyamoto T, Ishibashi T, Yamasaki S. Human mincle binds to cholesterol crystals and triggers innate immune responses. J Biol Chem. 2015;290(42):25322-25332.
33. Braza F, Brouard S, Chadban S, Goldstein DR. Role of TLRs and DAMPs in allograft inflammation and transplant outcomes. Nat Rev Nephrol. 2016;12(5):281-290.
34. Dwyer GK, Turnquist HR. Untangling local pro-inflammatory, reparative, and regulatory damage-associated molecular-patterns (DAMPs) pathways to improve transplant outcomes. Front Immunol. 2021;12:611910.
35. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and damage-associated molecular patterns (DAMPs). Am J Transplant. 2016;16(12):3338-3361.
36. Matta BM, Reichenbach DK, Blazar BR, Turnquist HR. Alarmins and their receptors as modulators and indicators of alloimmune responses. Am J Transplant. 2017;17(2):320-327.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Hasgur S, Yamamoto Y, Fan R, et al. Macrophage-inducible C-type lectin activates B cells to promote T cell reconstitution in heart allograft recipients. Am J Transplant. 2022;22:1779-1790. doi:10.1111/ajt.17033